Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer

Stopped early · Phase 2

Conditions studied: Non-small Cell Lung Cancer

In brief

The purpose of this study is to develop new treatments that will hopefully result in the relief of symptoms and prolongation of life. For this reason, your doctors have offered you treatment with a new experimental drug called PS 341.

Key facts

Study ID

NCT00200382

Run by

Rasim Gucalp

People needed

27

Starts

2004-05-01

Expected to finish

2007-05-01

Last updated by the study team

2018-08-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have confirmed NSCLC (squamous, adeno- and large cell anaplastic carcinoma)stage III B or Stage IV.
• No prior chemotherapy regimen Patients must have adequate organ and marrow function

You may not qualify if…

• Untreated symptomatic brain metastasis Patients with known HIV positivity

Where it is running

• HealthAlliance Hospitals — Fitchburg, Massachusetts, United States
• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
• Albert Einstein Cancer Center — The Bronx, New York, United States
• Jacobi Medical Center — The Bronx, New York, United States
• Montefiore Medical Center — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.